U.S. markets open in 1 hour 52 minutes

Eiger BioPharmaceuticals, Inc. (EIGR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.3300-0.0400 (-10.81%)
At close: 04:00PM EDT
0.3400 +0.01 (+3.03%)
After hours: 07:26PM EDT

Eiger BioPharmaceuticals, Inc.

2155 Park Boulevard
Palo Alto, CA 94306
United States
650 272 6138

Full Time Employees56

Key Executives

NameTitlePayExercisedYear Born
Dr. David Apelian M.B.A., M.D., MBA, Ph.D.CEO & Director204.39kN/A1965
Dr. Jeffrey S. Glenn M.D., Ph.D.Scientific Founder & Independent Director67kN/A1963
Mr. Eldon C. Mayer III, M.B.A.Chief Commercial Officer586.96kN/A1961
Mr. William G. Kaichoff CPA, CPACFO and Principal Financial & Accounting OfficerN/AN/A1966
Mr. Christopher A. KurtzChief Technical OfficerN/AN/A1967
Mr. James Vollins J.D.Gen. Counsel, Chief Compliance Officer & Corp. Sec.N/AN/A1969
Dr. Ingrid C. ChoongSr. VP of Clinical Devel.N/AN/AN/A
Dr. Colin Hislop M.D., MBBSSr. VP of Clinical & Devel. OperationsN/AN/A1958
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Corporate Governance

Eiger BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2023 is 9. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.